Headquartered in Gaithersburg, MD Fiscal year ends December NASDAQ: ALT altimmune.com
Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for patients with serious liver diseases. Its lead candidate, pemvidutide, is a novel peptide dual receptor agonist with balanced 1:1 glucagon/GLP-1 activity designed to reduce liver fat, inflammation, and fibrosis. Pemvidutide is being developed for three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The glucagon receptor activation provides direct liver effects, while GLP-1 receptor activation mediates metabolic effects including appetite suppression, weight loss, and pathways related to craving and reward. The company has received FDA Breakthrough Therapy Designation for MASH and Fast Track designations for both MASH and AUD. Altimmune trades on the Nasdaq under the ticker ALT and is currently pre-revenue, funding operations through equity offerings and debt financing. Updated
Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one…
Short interest is always a sign of how bearish investors may be on a stock. But it can also serve as a potential sign of a coming short squeeze, especially if the…
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
Thursday’s additional top analyst upgrades and downgrades were on Ally Financial, Altimmune, Capital One Financial, GoodRx, Leslie’s, PagSeguro Digital, Regions Financial, Sirius XM, StoneCo, Tencent Music Entertainment and more.
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Wednesday's top analyst upgrades and downgrades included Alphabet, Canopy Growth, Cinemark, Dick's Sporting Goods, Facebook, IMAX, Microsoft, Salesforce.com and SBA Communications.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Chris Lange Thursday's top analyst upgrades and downgrades included Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter and Under Armour.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Chris Lange Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing agreement the vaccine candidate.
Chris Lange Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
Chris Lange 24/7 Wall St. has tracked some stocks that either are defensive in general or are defying Monday's big drop because they have some aspect of their business that might be immune to…
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.
Chris Lange Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for patients with serious liver diseases. Its lead candidate, pemvidutide, is a novel peptide dual receptor agonist with balanced 1:1 glucagon/GLP-1 activity designed to reduce liver fat, inflammation, and fibrosis.
The Wall Street consensus 12-month price target for ALT is $17.11.
